Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.46 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2472396 | 0.75 | MAOA (0.46) | CYP1A2PTPN22NPC1MAPTRAB9A | |
| SCHEMBL13085236 | 0.72 | HPRT1 (0.57) | CYP1A1CYP1B1CYP1A2PTPN22RAB9A | |
| SCHEMBL30154374 | 0.72 | HPRT1 (0.57) | CYP1A1CYP1B1CYP1A2PTPN22RAB9A | |
| SCHEMBL30819315 | 0.72 | ALDH1A1 (0.55) | TRPM4KDM4EMAPTNPSR1TDP1 | |
| SCHEMBL467777 | 0.72 | ALDH1A1 (0.55) | TRPM4KDM4EMAPTNPSR1TDP1 | |
| SCHEMBL11942389 | 0.71 | HPRT1 (0.55) | CYP1A1CYP1B1CYP1A2PTPN22KDM4E | |
| SCHEMBL11545615 | 0.70 | CYP1A2 (0.54) | CYP1B1CYP1A2PTPN22TRPM4KDM4E | |
| SCHEMBL22892555 | 0.69 | POLB (0.43) | CYP1A1CYP1B1CYP1A2PTPN22MAPT | |
| SCHEMBL12070495 | 0.68 | CYP1B1 (0.49) | CYP1A1CYP1B1CYP1A2KDM4ENPC1 | |
| SCHEMBL22591653 | 0.68 | PTPN22 (0.44) | CYP1A1CYP1B1CYP1A2PTPN22NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370422-B1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-9149476-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8927591-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| EP-2370422-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | Fibrogen, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-7795299-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-14 | — | — | US | disclosed |
| WO-2010056767-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20090118356-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| US-7495026-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | CYP1A1 220/4885CYP1B1 594/4885CYP1A2 406/4885 |
| US-20090118356-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | BRCA1, CYP19A1, HUNK | CYP1A1 2318/4885CYP1B1 1102/4885CYP1A2 1678/4885 |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | CYP1A1 220/4885CYP1B1 594/4885CYP1A2 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.